Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) Meeting Abstract
| Authors: | Andre, T.; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D. M.; Garcia-Carbonero, R.; Alcaide, J.; Gibbs, P.; De La Fouchardiere, C.; Rivera, F.; Elez, E.; Bendell, J. C.; Le, D. T.; Yoshino, T.; Zhong, W. Y.; Fogelman, D. R.; Marinello, P.; Diaz, L. A. |
| Abstract Title: | Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120601315 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.3500 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3500 -- Source: Wos |
